tirzepatide for weight loss approval F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Tirzepatide, the new FDA approved

On March 5, Novo Nordisk released the top-line results from this pivotal kidney outcomes trial: Use of semaglutide in patients with diabetic kidney disease reduced the primary outcomea composite of kidney failure, 50% decline in estimated glomerular filtration rate (eGFR), and cardiovascular (CV) or kidney deathby an impressive 24% (Figure 1)

Chronic reliance on antacids suggests inadequately controlled disease requiring more definitive intervention

The exact dose depends on individual response, and finding it requires careful downward titration with monitoring

Thats how these medications help people manage type 2 diabetes